Open AccessGlioblastoma with Oligodendroglioma Component ( GBM ‐ O ): Molecular Genetic and Clinical Characteristics
Author(s) -
Appin Christina L.,
Gao Jingjing,
Chisolm Candace,
Torian Mike,
Alexis Dianne,
Vincentelli Cristina,
Schniederjan Matthew J.,
Hadjipanayis Costas,
Olson Jeffrey J.,
Hunter Stephen,
Hao Chunhai,
Brat Daniel J.
Publication year - 2013
Publication title -
brain pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.986
H-Index - 132
eISSN - 1750-3639
pISSN - 1015-6305
DOI - 10.1111/bpa.12018
Subject(s) - oligodendroglioma , pten , immunohistochemistry , glioblastoma , fluorescence in situ hybridization , cancer research , glioma , astrocytoma , temozolomide , biology , medicine , pathology , gene , genetics , apoptosis , pi3k/akt/mtor pathway , chromosome
Abstract Glioblastoma ( GBM ) is an aggressive primary brain tumor with an average survival of approximately 1 year. A recently recognized subtype, glioblastoma with oligodendroglioma component ( GBM ‐ O ), was designated by the W orld H ealth O rganization ( WHO ) in 2007. We investigated GBM ‐ O s for their clinical and molecular characteristics as compared to other forms of GBM . Tissue samples were used to determine EGFR , PTEN , and 1p and 19q status by fluorescence in situ hybridization ( FISH ); p53 and mutant IDH 1 protein expression by immunohistochemistry ( IHC ); and MGMT promoter status by methylation‐specific polymerase chain reaction ( PCR ). GBM ‐ O s accounted for 11.9% of all GBMs . GBM ‐ O s arose in younger patients compared to other forms of GBMs (50.7 years vs. 58.7 years, respectively), were more frequently secondary neoplasms, had a higher frequency of IDH 1 mutations and had a lower frequency of PTEN deletions. Survival was longer in patients with GBM ‐ O s compared to those with other GBMs , with median survivals of 16.2 and 8.1 months, respectively. Most of the survival advantage for GBM ‐ O appeared to be associated with a younger age at presentation. Among patients with GBM ‐ O , younger age at presentation and 1p deletion were most significant in conferring prolonged survival. Thus, GBM ‐ O represents a subset of GBMs with distinctive morphologic, clinical and molecular characteristics.